RA Capital Management and TPG Biotech provided the series A financing, as Shin Nippon Biomedical Laboratories spun out migraine treatment startup Satsuma Pharmaceuticals.
US-based migraine therapy developer Satsuma Pharmaceuticals has spun out from contract pharmaceutical research services provider Shin Nippon Biomedical Laboratories (SNBL) with $12m in series A financing.
RA Capital Management and TPG Biotech co-led the round, and RA Capital managing director Rajeev Shah and TPG Biotech managing director Heath Lukatch are joining Satsuma’s board of directors.
Satsuma will direct the series A capital to the development of its lead product candidate, STS101, which combines existing anti-migraine drug dihydroergotamine with Japan-based SNBL’s…
